Together these data suggest that EGFR-driven ESCC, identified by EGFR CNG and /or EGFR protein overexpression are likely to be less sensitive to nivolumab which is unlikely as a monotherapy to provide an effective treatment for this group of patients. The gene discussed is EGFR; the disease is esophageal squamous cell carcinoma.